Background
==========

Cyclosporin A (CSA) is a calcineurin inhibitor routinely used as graft-versus-host-disease (GvHD) prophylaxis after haematopoietic stem cell transplantation (HSCT). Common CSA related side-effects include renal dysfunction, arterial hypertension, hepatic toxicity, gingival hyperplasia, hypertrichosis, opportunistic infections and tremors\[[@B1]\]. Severe neurotoxicity such as confusion, disorientation, decreased responsiveness, visual hallucinations, delusions, seizures, pyramidal motor weakness, cortical blindness, aphasia and ataxia is reported in 4% to 11% patients undergoing HSCT \[[@B2]-[@B6]\]. Unfortunately neurotoxicity can occur both at therapeutic and at high CSA levels \[[@B2],[@B3]\]. The reported incidence of CSA neurotoxicity post HSCT may be underestimated because the clinical picture could be confused with other neurological complications such as infections, metabolic disturbances (hypomagnesaemia, hypocolesterolaemia, hypo/hypernatraemia, hypercalcaemia), toxic encephalopathy (drug induced by intratecal or systemic chemotherapeutic agents, oppioids, amphotericin B or radiotherapy), thrombotic microagiopathy, vascular events and structural neurological lesions\[[@B4]\]. Many risk factors for the development of CSA-related neurotoxicity have been investigated, including the use of methylprednisolone, arterial hypertension, fluid overload, hypocholesterolaemia, hypomagnesaemia and pre-existing brain disease\[[@B5],[@B7]\]. The brain magnetic resonance imaging (MRI) finding usually associated to CSA neurotoxicity is known as posterior reversible leukoencephalopathy syndrome (PRES), typically distributed in the posterior regions of the white matter of the brain \[[@B5]-[@B8]\]. In general the prognosis of CSA neurotoxicity is good\[[@B4]\] and posterior leukoencephalopathy usually resolves completely with dose reduction or drug withdrawal. However, some cases of non-reversible encephalopathy syndrome have been described with occurrence of late epilepsy and late persistent electroencephalogram (EEG) abnormalities \[[@B9],[@B10]\].

We report 6 cases of CSA related neurotoxicity occurring among 67 children undergoing HSCT for haemoglobinopaties and discuss early diagnosis and management.

Methods
=======

Patients\' characteristics
--------------------------

A total of 67 pediatric patients affected by haemoglobinopaties underwent matched related HSCT at our Institute between June 2005 and Nov 2008. Children were referred to our center by Mediterranean and Middle East Countries. Cost of treatment was covered by a cooperation program funded by the Mediterranean Institute of Haematology <http://www.fondazioneime.org>. Among these, 6 patients (9%) had evidence of severe CSA related neurotoxicity requiring CSA discontinuation. The underlying disease was beta thalassemia major (n = 5) or sickle cell disease (SCD, n = 1). Patients\' characteristics are shown in table [1](#T1){ref-type="table"}. According to the risk classes described by Lucarelli\[[@B11]\], 3 thalassemia patients were classified as class II and 2 as class III. None of the patients had preexisting neurologic deficits. Baseline neurological involvement was excluded in the SCD patient by MRI and EEG. Conditioning regimen is summarized in table [2](#T2){ref-type="table"}. All patients received seizures prophylaxis with oral clonazepam (0.05 mg/kg/day) starting 24 hours before the first busulfan dose to 24 hours after the last dose.

###### 

Patient\'s characteristics

  -----------------------------------------------------------------------------------------------------------------------
  Patient number                      \#1            \#2          \#3          \#4          \#5            \#6
  ----------------------------------- -------------- ------------ ------------ ------------ -------------- --------------
  **Age**\                            14             9            12           8            11             17
  (yrs)                                                                                                    

                                                                                                           

  **Gender**\                         M              F            M            F            F              M
  (M/F)                                                                                                    

                                                                                                           

  **Country of origin**               Egypt          Lebanon      Iraq         Syria        Syria          Syria

                                                                                                           

  **Diagnosis (Class)**               SCD            B-thal (2)   B-thal (3)   B-thal (3)   B-thal (2)     B-thal (2)

                                                                                                           

  **AST/ALT**\                        69/18          44/12        65/73        64/79        62/68          20/33
  (U/L) pre HSCT                                                                                           

                                                                                                           

  **Ferritin**\                       3344           1855         3003         4930         3422           1287
  (ng/ml) pre HSCT                                                                                         

                                                                                                           

  **Portal fibrosis**\                G1/S4          G1/S1        G7/S4        G5/S3        G3/S3          G1/S1
  Ishak grading (G) and staging (S)                                                                        

                                                                                                           

  **Iron chelation**                  irregular      regular      irregular    irregular    regular        irregular

                                                                                                           

  **HCV status**(Ab/RNA)              HCVAb+ RNA -   HCVAb -\     HCVAb+\      HCVAb -\     HCVAb -RNA -   HCVAb+ RNA -
                                                     RNA -        RNA +        RNA -                       
  -----------------------------------------------------------------------------------------------------------------------

###### 

Conditioning regimen

  ------------------------------------------------------------------
                   Pre-conditioning\         Conditioning\
                   (-45 to -12)              (-11 to -2)
  ---------------- ------------------------- -----------------------
  B-thal/Class 2   //                        iv Bu^§^Cy 200 mg/kg

                                             

  B-thal/Class 3   AZ/HU\                    iv Bu^§^Cy 160 mg/kg\
                   Fludarabine 150 mg/m^2^   ATG 7.5 mg/kg

                                             

  SCD              AZ/HU\                    iv Bu^§^Cy 200 mg/kg\
                   Fludarabine 150 mg/m^2^   ATG 10 mg/kg
  ------------------------------------------------------------------

CSA administration and monitoring
---------------------------------

GvHD prophylaxis consisted of CSA, short course of iv Methotrexate (MTX) 10 mg/m2 on d 1, 3 and 6 and metilprednisolone 0.5 mg/kg from d -1 until d 25. ATG was added in 3 patients.

CSA was used orally at the dose of 10 mg/kg/day from day -2. The dose was adjusted to a trough plasma level of 150-250 ng/mL with twice weekly monitoring. In the absence of GvHD, CSA was tapered from d 60 until discontinuation at 1 year.

Monitoring for CSA related side effects consisted of daily examination, 6 hourly blood pressure and daily blood routine biochemistry including magnesium till day 30, followed by 3 times weekly till day 60. Arterial hypertension above 75° percentile for age and weight was treated with oral calcium antagonists. Fluid overload was treated with iv furosemide. Magnesium was supplemented for plasma levels below 0.8 mmol/Lt. Children developing CSA neurotoxicity underwent neuro-radiological (MRI scan) and electrophysiological studies (EEG). In case of epileptic signs, EEG was repeated after 24 hours and then on regular basis in order to monitor the outcome of the anticonvulsive therapy. CSA-related toxicity was evaluated using the National Cancer Institute common toxicity criteria (NCI/CTC). Clinical management was lead by the HSCT specialists on the HSCT ward with the collaboration of intensivists, neurologists, neurophysiologists and neuroradiologists.

Results
=======

Clinical course
---------------

All six patients developing neurotoxicity presented prodromes 1-2 days before overt neurotoxicity. Prodromes were arterial hypertension (n = 5), headache (n = 2), visual disturbances (n = 1) or vomiting (n = 1). Symptoms of CSA neurological toxicity were characterized by: generalized seizures (grade 3-4 neurotoxicity) (n = 4), endocranial hypertension evidenced by impaired level of consciousness (grade 3 confusion) associated to bradycardia, arterial hypertension and cerebral vomiting (n = 1), and blurred vision (grade 3 visual toxicity) (n = 1). The median day of appearance was 11 days after HSCT (range +1 to +40). When neurological symptoms appeared, CSA plasma levels were in range in all patients (median 178, range 69-250 ng/ml). Clinical and laboratory findings are summarized in Table [3](#T3){ref-type="table"}. None of the patients had evidence of thrombotic microangiopathy. None of the clinical pictures were suggestive for viral encephalitis, as evidenced by apyrexia, normal CRP, negative molecular virological screening on plasma, non suggestive MRI and EEG pictures.

###### 

Characteristics and treatment of CSA related neurotoxicity

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient number                 \#1                   \#2              \#3             \#4             \#5                         \#6
  ------------------------------ --------------------- ---------------- --------------- --------------- --------------------------- ----------------------
  Day of onset post HSCT         1                     5                40              20              7                           15

                                                                                                                                    

  CSA levels (ng/ml)             69                    250              194             179             177                         150

                                                                                                                                    

  Mg levels (mEq/l)              0.88                  0.86             0.95            0.72            0.85                        1.03

                                                                                                                                    

  Cholesterol and\               123/82                152/64           125/137         195/139         136/162                     177/79
  tryglicerides levels (mg/dl)                                                                                                      

                                                                                                                                    

  Prodromes                      headache & vomiting   headache & HTN   HTN             HTN             HTN                         HTN & blurred vision

                                                                                                                                    

  Neurological signs             gen seiz              confusion        gen seiz        gen seiz        gen seiz                    blurred vision

                                                                                                                                    

  Acute treatment                LOR\                  mannitol\*       LOR\            LOR\            LOR\                        mannitol\*
                                 P\                                     P               P               P                           
                                 PB                                                                                                 

                                                                                                                                    

  Chronic treatment              P\                    none             P               P               P                           P\
                                 PB                                                                                                 CLO

                                                                                                                                    

  Outcome (day last follow-up    Alive & well\         Alive & well\    Alive & well\   Alive & well\   Died, grade IV GVHD (+60)   Alive & well\
                                 (+1065)               (+1059)          (+1005)         (+760)                                      (+320)
  --------------------------------------------------------------------------------------------------------------------------------------------------------

Mg = magnesium

HTN = arterial hypertension

gen seiz = generalized seizures

LOR = lorazepam 0.05 mg/kg/dose iv

P = phenitoyn 15 mg/kg/dose iv for acute treatment

phenitoyn 7 mg/kg/day iv for maintenance treatment

PB = Phenobarbital 7 mg/kg/day iv

\* 0.5 g/kg/dose iv

CLO = oral clonazepam 0.05 mg/kg/day

Neuroradiological and electrophysiological findings
---------------------------------------------------

Neuroradiological and electrophysiological studies were performed within 24 hours from neurological symptoms appearance. A CT scan performed in patient \#5 because MRI was not immediately available showed a minimal subdural haemorrhagic layer compatible with post epileptic trauma. MRI was performed in all patients. In 5/6 patients, MRI showed a symmetric involvement of the posterior portions of the cerebral hemispheres, while one case showed abnormal signals hyperintense in T2 and Flair images in the cerebellar hemispheres, involving predominantly the white matter but also the cortex (figure [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). In 5 out of the 6 patients studied, a moderate gyral swelling was present. On diffusion weighted images these lesions had an increase diffusion (hyperintens sygnal on apparent diffusion coefficient maps) consistent with vasogenic oedema.

![**MRI-flair axial study of the brain (patient \#1) showing cortical and subcortical spots with a mild mass effect, with major spreading in the cerebellum (right hemisphere \> left hemisphere)**.](1824-7288-36-14-1){#F1}

![**MRI-flair axial study of the brain (patient \#3) showing multiple cortical and subcortical spots involving both occipital hemispheres**.](1824-7288-36-14-2){#F2}

In five out of 6 children, it was possible to perform an EEG at the time of the neurological symptoms onset. EEG of three out of five patients showed a status epilepticus (Figure [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). The other two patients showed, respectively, a focal delta activity and focal epileptiform discharges. EEGs were repeated every 2-3 days in the acute phase in order to adjust the anticonvulsive therapy.

![**Pt \# 1 EEG pattern of a seizure, with left occipital onset, during status epilepticus**. Each seizure was close to the next one, with an inter critical activity lasting 10-30 seconds. In the majority of cases seizures were not related to an evident modification of the clinical status.](1824-7288-36-14-3){#F3}

![**Pt \# 5 EEG pattern of a seizure, with right fronto-temporal onset**. Seizures were repeated every 20-40 minutes. During the seizures no clear modification of the clinical status was observed.](1824-7288-36-14-4){#F4}

![**Same patient as figure 4**. Ending of the seizure with contra-lateral diffusion of the epileptic abnormalities. During this phase the patient was able to answer questions and could name objects correctly. No motor epileptic sign of seizure were present.](1824-7288-36-14-5){#F5}

Treatment
---------

On occurrence of neurotoxicity, CSA was immediately withdrawn. After 2 days of calcineurin-inhibitor washout, tacrolimus alone (n = 3) or tacrolimus and mycophenolate mofetile (n = 3) (according to the individual GvHD risk) were introduced with tacrolimus level monitoring. Neurological symptoms resolved within 2-3 days following CSA withdrawal and did not re-occur during tacrolimus treatment. Intravenous lorazepam was immediately administered at seizures unset, followed by anticonvulsive treatment with phenitoyn. Patient \#1 (SCD) required association with phenobarbital to control generalized seizures (table [3](#T3){ref-type="table"}). Intravenous mannitol was used successfully in patient \#2 and \#6 to treat confusion, vomiting, headache and blurred vision related to endocranial hypertension. Anticonvulsive therapy was tapered and stopped after normalization of EEG findings. In patient \#6 phenitoyn was withdrawn after 3 weeks of treatment because of the onset of a severe hepatic-toxicity (elevation of liver enzymes and bilirubin) in the presence of a liver biopsy suggestive of drug-related injury. Liver function normalized following phenitoyn discontinuation. Anticonvulsive therapy was continued with clonazepam only, without seizure recurrence.

Outcome

Neuroradiological monitoring was performed by MRI every 7-14 days until complete remission of the diffuse signal alterations, which occurred after a median of 15 days (range 12-90 days) from CSA withdrawal. Non epileptiform EEG abnormalities were still detectable in all patients in the 15 days after the onset of symptoms. The complete normalization of EEG occurred after a median of 120 days (range 60-140 days). Five patients are alive and symptoms-free at a median follow up of 1005 days (range 320-1065) without neurological sequelae, while one patient died on day 60 for grade IV GvHD, without neurological symptoms.

Discussion
==========

CSA neurotoxicity is a well recognized complication observed after HSCT. Incidence of neurotoxicity in patients receiving allogeneic HSCT varies according to the underlying disease\[[@B6]\]. In the paediatric age incidence in haematological malignancies ranges between 4% and 11% \[[@B3],[@B12]\]. The incidence is higher in non malignant disorders, although very few data have been published. In patients affected by haemoglobinopaties, a single published series suggests a very high incidence of CSA related neurotoxicity (28.8%)\[[@B7]\]. We describe a large and homogenous series of children with haemoglobinopaties who experienced a 9% incidence of CSA neurotoxicity following HSCT. Our data confirm previous findings on increased risk of CSA related severe neurotoxicity in patients with non malignancies, but suggests that, up to date, early diagnosis and intervention may ameliorate the incidence and severity. Patients with hemoglobinopaties may be at increased risk of neutoxicity due to impaired liver function secondary to iron overload as consequence of irregular iron chelation and blood-born viral infection. Both risk factors were heavily present in our series and the series reported by Erer et al\[[@B7]\]. CSA is metabolized in the liver as the drug is converted by the iso-enzymes of hepatic cytochrome P450. Impaired hepatic function may thus affect CSA metabolism triggering neurotoxicity. Another factor which may have influenced the onset of seizures is the use of iv busulfan in the preparative regimen. It has been reported that busulfan may induce seizures at the time of administration, and this may play a role in the subsequent appearance of neurotoxicity due to CSA. However, our policy of therapeutic dose adjustment and seizure prophylaxis during administration did not result in any immediate neurological toxicity.

Moreover, our results suggest that early patients\' monitoring by neuro-radiological and electrophysiological studies and improved awareness of prodromes can reduce the incidence and long-term consequences of these events. Among the prodromes, arterial hypertension was the most premature and should therefore routinely evaluated and promptly intervened on. In our series, prompt discontinuation of CSA resulted in good prognosis with no neurological sequels. As alternative GvHD prophylaxis, we opted for tacrolimus. This calcineurin inhibitor, although similar to CSA in mechanism and metabolism, did not produce neurological side effects in this series.

Conclusions
===========

Our results confirm the high incidence of CSA related neurotoxicity in patients with non malignant disorders undergoing HSCT. This could be explained by their impaired organ functions due to the underlying disease or need for higher CSA doses. The awareness of prodromes of CSA related neurotoxicity (arterial hypertension, headache and visual disturbances) and early recognition with electrophysiological and imaging strategies is very important for prompt intervention on these patients, in order to reduce the risk of CSA related neurological events, in particular irreversible sequels. Our experience confirms that the gold standard approach to evaluate CSA related brain lesions is MRI, highly sensitive to detect the posterior diffuse alterations consistent with vasogenic oedema typical for PRES, and that CSA withdrawal should be prompt to prevent irreversible sequels.
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